BioSpace News Archive

Day One Biopharmaceuticals announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the Company’s lead product candidate, DAY101, for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children.

LifeSignals Inc., announced it has received FDA Class II 510 approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.

Umoja Biopharma announced the appointments of three new hires in the company’s research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.

Harrow Health, Inc., an ophthalmic‑focused healthcare company, announced that it has entered into an agreement with Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions, to acquire the marketing and supply rights in the U.S. and Canada for AMP-100, a patented ophthalmic surgical drug candidate.

IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases, has announced the completion of a $16.5 million Series A financing round.

Valo Health, LLC (“Valo”), the technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence driven compute, today announced its acquisition of Courier Therapeutics.

Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021.

IACTA Pharmaceuticals, Inc. (IACTA), an innovation leader in ophthalmic therapeutics, today announced the appointment of Yogesh Bahl as Chief Financial Officer (CFO) and Eric Carter, M.D., Ph.D., as Chief Medical Officer (CMO).

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), today presents data updates from MARIO-275, the Company’s randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced UC as well as data from MARIO-3,

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.